LT2906252T - Pirolobenzodiazepino-anti-her2 antikūno konjugatai - Google Patents
Pirolobenzodiazepino-anti-her2 antikūno konjugataiInfo
- Publication number
- LT2906252T LT2906252T LTEP13788691.7T LT13788691T LT2906252T LT 2906252 T LT2906252 T LT 2906252T LT 13788691 T LT13788691 T LT 13788691T LT 2906252 T LT2906252 T LT 2906252T
- Authority
- LT
- Lithuania
- Prior art keywords
- pyrrolobenzodiazepine
- her2 antibody
- antibody conjugates
- conjugates
- her2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261712928P | 2012-10-12 | 2012-10-12 | |
| US201261712924P | 2012-10-12 | 2012-10-12 | |
| US201361784249P | 2013-03-14 | 2013-03-14 | |
| US201361784270P | 2013-03-14 | 2013-03-14 | |
| US201361784233P | 2013-03-14 | 2013-03-14 | |
| PCT/EP2013/071343 WO2014057115A1 (en) | 2012-10-12 | 2013-10-11 | Pyrrolobenzodiazepine-anti-her2 antibody conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2906252T true LT2906252T (lt) | 2017-09-11 |
Family
ID=49552324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP13788691.7T LT2906252T (lt) | 2012-10-12 | 2013-10-11 | Pirolobenzodiazepino-anti-her2 antikūno konjugatai |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150273077A1 (lt) |
| EP (1) | EP2906252B1 (lt) |
| JP (1) | JP2016502504A (lt) |
| KR (1) | KR20150083856A (lt) |
| CN (1) | CN104955485B (lt) |
| AU (1) | AU2013328621B2 (lt) |
| BR (1) | BR112015008177A2 (lt) |
| CA (1) | CA2887896A1 (lt) |
| CY (1) | CY1119287T1 (lt) |
| DK (1) | DK2906252T3 (lt) |
| ES (1) | ES2640449T3 (lt) |
| HR (1) | HRP20171264T1 (lt) |
| HU (1) | HUE034505T2 (lt) |
| LT (1) | LT2906252T (lt) |
| MX (1) | MX2015004423A (lt) |
| PL (1) | PL2906252T3 (lt) |
| PT (1) | PT2906252T (lt) |
| RS (1) | RS56222B1 (lt) |
| SI (1) | SI2906252T1 (lt) |
| SM (1) | SMT201700444T1 (lt) |
| WO (1) | WO2014057115A1 (lt) |
| ZA (1) | ZA201502267B (lt) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| CA2795349C (en) | 2010-04-15 | 2016-11-29 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazepine conjugates |
| JP5875083B2 (ja) | 2010-04-15 | 2016-03-02 | メディミューン リミテッド | 増殖性疾患治療用ピロロベンゾジアゼピン |
| SG11201400770SA (en) | 2011-09-20 | 2014-04-28 | Spirogen Sarl | Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates |
| EP2751111B1 (en) | 2011-10-14 | 2017-04-26 | MedImmune Limited | Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| AU2012322932B2 (en) | 2011-10-14 | 2016-11-10 | Medimmune Limited | Pyrrolobenzodiazepines |
| CN103997893B (zh) | 2011-10-14 | 2019-04-12 | 西雅图基因公司 | 吡咯并苯并二氮杂卓和靶向结合物 |
| MX338711B (es) | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| EP2906249B1 (en) | 2012-10-12 | 2018-06-27 | MedImmune Limited | Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation |
| HRP20190366T1 (hr) | 2012-10-12 | 2019-04-19 | Medimmune Limited | Pirolobenzodiazepini i njihovi konjugati |
| CN110627797A (zh) | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
| AU2014229529B2 (en) | 2013-03-13 | 2018-02-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| TWI680766B (zh) | 2013-03-13 | 2020-01-01 | 英商梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
| GB201317981D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3193940A1 (en) * | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| LT3191135T (lt) | 2014-09-12 | 2020-11-25 | Genentech, Inc. | Anti-her2 antikūnai ir imunokonjugatai |
| MX2017003472A (es) * | 2014-09-17 | 2017-10-31 | Genentech Inc | Inmunoconjugados que comprenden anticuerpos anti-her2. |
| CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| US9504694B2 (en) * | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| GB201506394D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506389D0 (en) * | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| CR20180243A (es) | 2015-10-02 | 2018-07-31 | Genentech Inc | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso |
| TWI727380B (zh) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性ｈｅｒ２抗體藥物共軛體 |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN106248971B (zh) * | 2016-08-19 | 2017-10-03 | 合肥瀚科迈博生物技术有限公司 | 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201619490D0 (en) * | 2016-11-17 | 2017-01-04 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| RS61795B1 (sr) | 2017-02-08 | 2021-06-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin antitela |
| HUE056289T2 (hu) | 2017-02-08 | 2022-02-28 | Adc Therapeutics Sa | Pirrolobenzodiazepin-antitest konjugátumok |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| CN110582505B (zh) | 2017-04-18 | 2021-04-02 | 免疫医疗有限公司 | 吡咯并苯并二氮杂*缀合物 |
| EP3612236A1 (en) | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Combination therapy with an anti-cd25 antibody-drug conjugate |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| BR112019026498A2 (pt) | 2017-06-14 | 2020-07-14 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd25 |
| KR102270107B1 (ko) | 2017-08-18 | 2021-06-30 | 메디뮨 리미티드 | 피롤로벤조디아제핀 컨쥬게이트 |
| NZ762505A (en) | 2017-09-29 | 2026-03-27 | Daiichi Sankyo Co Ltd | Antibody-pyrrolobenzodiazepine derivative conjugate |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| EP3774923A4 (en) | 2018-03-28 | 2021-12-29 | Mitsubishi Tanabe Pharma Corporation | Drug conjugates of cmet monoclonal binding agents, and uses thereof |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US11141490B2 (en) * | 2018-07-13 | 2021-10-12 | Research Foundation Of The City University Of New York | Antibody-drug conjugates based on gold compounds |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
| WO2020196475A1 (ja) * | 2019-03-25 | 2020-10-01 | 第一三共株式会社 | 抗ｈｅｒ２抗体－ピロロベンゾジアゼピン誘導体コンジュゲート |
| GB201908128D0 (en) * | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| CA3148611A1 (en) | 2019-08-12 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (mst1r) variants and uses thereof |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| EP4548932A1 (en) | 2022-06-30 | 2025-05-07 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005085251A1 (en) * | 2004-03-01 | 2005-09-15 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| GB0508084D0 (en) * | 2005-04-21 | 2005-06-01 | Spirogen Ltd | Pyrrolobenzodiazepines |
| US20080112961A1 (en) * | 2006-10-09 | 2008-05-15 | Macrogenics, Inc. | Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| GB0819095D0 (en) * | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| EP2445539A4 (en) * | 2009-06-26 | 2015-05-20 | Five Prime Therapeutics Inc | VALIDATION OF TARGETS OF THERAPEUTIC ANTIBODIES AND IN VIVO SCREENING |
| CA2795349C (en) * | 2010-04-15 | 2016-11-29 | Seattle Genetics, Inc. | Targeted pyrrolobenzodiazepine conjugates |
| JP5875083B2 (ja) * | 2010-04-15 | 2016-03-02 | メディミューン リミテッド | 増殖性疾患治療用ピロロベンゾジアゼピン |
| SI2528625T1 (sl) * | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| US9586996B2 (en) * | 2010-04-30 | 2017-03-07 | Esperance Pharmaceuticals, Inc. | Lytic-peptide-Her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use |
| MX393973B (es) * | 2011-05-08 | 2025-03-24 | Legochem Biosciences Inc | Conjugados de proteína-agente activo y método para su preparación. |
| BR112014009050B1 (pt) * | 2011-10-14 | 2022-06-21 | Medimmune Limited | Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas |
| WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
-
2013
- 2013-10-11 SI SI201330762T patent/SI2906252T1/sl unknown
- 2013-10-11 PT PT137886917T patent/PT2906252T/pt unknown
- 2013-10-11 JP JP2015536163A patent/JP2016502504A/ja active Pending
- 2013-10-11 DK DK13788691.7T patent/DK2906252T3/en active
- 2013-10-11 ES ES13788691.7T patent/ES2640449T3/es active Active
- 2013-10-11 PL PL13788691T patent/PL2906252T3/pl unknown
- 2013-10-11 CN CN201380065413.1A patent/CN104955485B/zh not_active Expired - Fee Related
- 2013-10-11 CA CA2887896A patent/CA2887896A1/en not_active Abandoned
- 2013-10-11 LT LTEP13788691.7T patent/LT2906252T/lt unknown
- 2013-10-11 US US14/434,810 patent/US20150273077A1/en not_active Abandoned
- 2013-10-11 HR HRP20171264TT patent/HRP20171264T1/hr unknown
- 2013-10-11 RS RS20170839A patent/RS56222B1/sr unknown
- 2013-10-11 AU AU2013328621A patent/AU2013328621B2/en not_active Ceased
- 2013-10-11 MX MX2015004423A patent/MX2015004423A/es unknown
- 2013-10-11 WO PCT/EP2013/071343 patent/WO2014057115A1/en not_active Ceased
- 2013-10-11 KR KR1020157012365A patent/KR20150083856A/ko not_active Withdrawn
- 2013-10-11 BR BR112015008177A patent/BR112015008177A2/pt not_active IP Right Cessation
- 2013-10-11 HU HUE13788691A patent/HUE034505T2/en unknown
- 2013-10-11 EP EP13788691.7A patent/EP2906252B1/en active Active
- 2013-10-11 SM SM20170444T patent/SMT201700444T1/it unknown
-
2015
- 2015-04-07 ZA ZA2015/02267A patent/ZA201502267B/en unknown
-
2017
- 2017-09-05 CY CY20171100933T patent/CY1119287T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20171264T1 (hr) | 2017-10-20 |
| DK2906252T3 (en) | 2017-09-11 |
| SMT201700444T1 (it) | 2017-11-15 |
| SI2906252T1 (sl) | 2017-10-30 |
| AU2013328621A1 (en) | 2015-04-23 |
| ZA201502267B (en) | 2017-09-27 |
| JP2016502504A (ja) | 2016-01-28 |
| WO2014057115A1 (en) | 2014-04-17 |
| KR20150083856A (ko) | 2015-07-20 |
| PT2906252T (pt) | 2017-09-19 |
| RS56222B1 (sr) | 2017-11-30 |
| PL2906252T3 (pl) | 2017-11-30 |
| CN104955485A (zh) | 2015-09-30 |
| CY1119287T1 (el) | 2018-02-14 |
| US20150273077A1 (en) | 2015-10-01 |
| MX2015004423A (es) | 2015-10-29 |
| CN104955485B (zh) | 2018-01-30 |
| CA2887896A1 (en) | 2014-04-17 |
| AU2013328621B2 (en) | 2016-12-01 |
| ES2640449T3 (es) | 2017-11-03 |
| EP2906252A1 (en) | 2015-08-19 |
| BR112015008177A2 (pt) | 2017-09-19 |
| HUE034505T2 (en) | 2018-02-28 |
| EP2906252B1 (en) | 2017-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2300020I1 (hu) | Pirrolobenzodiazepin-antitest konjugátumok | |
| IL264558A (en) | Anti–il–23p19 antibodies | |
| ZA201502267B (en) | Pyrrolobenzodiazepine-anti-her2 antibody conjugates | |
| SI2906253T1 (sl) | Konjugati pirolobenzodiazepin-protitelo proti PSMA | |
| LT2906251T (lt) | Pirolobenzodiazepino-anti-cd22 antikūno konjugatai | |
| ZA201502523B (en) | Pyrrolobenzodiazepine-anitbody conjugates | |
| IL235042B (en) | Anti–fcrn antibodies | |
| IL234848A0 (en) | Protease controlled antibodies | |
| IL236259A0 (en) | Anti 15–siglec antibodies | |
| ZA201407316B (en) | Anti-fgfr2 antibody | |
| ZA201407079B (en) | Cdr-modified anti-siglec-15 antibody | |
| GB201220242D0 (en) | Antibody | |
| EP2811018A4 (en) | ANTI-BODY ANTI-sAPPß | |
| IL235188A0 (en) | Antibodies against c-pdgf |